Therapeutic proteins

AI and robotics
#Artificial intelligence (AI) #Generate:Biomedicines #Novartis #Partnership #Therapeutic proteins

Novartis and Generate partner on AI-created protein therapeutics

Novartis and Generate:Biomedicines have announced a multi-target collaboration to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate’s generative AI platform, ​‘The Generate Platform’, to create potentially first- and best-in-class molecules through AI-based optimisation and de novo generation. The collaboration will combine The Generate Platform, which… Read More

#Business & Investment #News

Antibody binding to the fusion protein of the respiratory syncytial virus
#Drug discovery #Fc-Fusion proteins #Protein chemistry / Proteomics #Therapeutic proteins #Whitepaper

Whitepaper: CMC for Fab and Fc-fusion development programmes

A new whitepaper is now available from Lonza Biologics entitled ‘A comprehensive and flexible approach to CMC for Fab and Fc-fusion development programs’. Read the whitepaper to: Gain insights into the diverse and complex structures of new molecular formats, often encompassing multiple chains and multiple domains Understand… Read More

#News

Lonza Biologics white paper
#Drug discovery #Fc-Fusion proteins #Protein chemistry / Proteomics #Therapeutic proteins

A comprehensive and flexible approach to CMC for Fab and Fc-fusion development programs

Read this whitepaper to: Gain insights into the diverse and complex structures of new molecular formats, often encompassing multiple chains and multiple domains Understand the unique challenges faced during the process development and manufacture of these advanced proteins Explore how characterising these products and developing robust manufacturing processes can help… Read More

#Resources

Interleukin-2 conjugate
#Autoimmune disease #Preclinical development #Therapeutic proteins #VALANX Biotech

Study proves efficacy of protein conjugate in autoimmune disease

VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. The findings demonstrate the potential of VLX101, a novel Interleukin-2 conjugate and the efficacy of the therapeutic approach. Protein drugs hold great… Read More

#News

Exome cross-section
#Evox Therapeutics #Exosomes #Therapeutic proteins

Advances continue for Evox’ exosome engineering platform 

Evox Therapeutics, an exosome therapeutics company, has published Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes in Nature Communications. This follows a research collaboration and option agreement with the Icahn School of… Read More

#News

#Biosecurity #Cell programming #Defense Advanced Research Projects Agency #Ginkgo Bioworks #Proteins #Therapeutic proteins #Therapeutics

Ginkgo Bioworks awarded DARPA contract for therapeutic proteins 

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.   As a performer on DARPA's Reimagining Protein Manufacturing… Read More

#News #Regulatory